Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas

In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonego, Benedetta, Ibatici, Adalberto, Rivoli, Giulia, Angelucci, Emanuele, Sola, Simona, Massone, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670482/
https://www.ncbi.nlm.nih.gov/pubmed/37998391
http://dx.doi.org/10.3390/cells12222656
_version_ 1785149315304390656
author Sonego, Benedetta
Ibatici, Adalberto
Rivoli, Giulia
Angelucci, Emanuele
Sola, Simona
Massone, Cesare
author_facet Sonego, Benedetta
Ibatici, Adalberto
Rivoli, Giulia
Angelucci, Emanuele
Sola, Simona
Massone, Cesare
author_sort Sonego, Benedetta
collection PubMed
description In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.
format Online
Article
Text
id pubmed-10670482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106704822023-11-20 Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas Sonego, Benedetta Ibatici, Adalberto Rivoli, Giulia Angelucci, Emanuele Sola, Simona Massone, Cesare Cells Review In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs. MDPI 2023-11-20 /pmc/articles/PMC10670482/ /pubmed/37998391 http://dx.doi.org/10.3390/cells12222656 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sonego, Benedetta
Ibatici, Adalberto
Rivoli, Giulia
Angelucci, Emanuele
Sola, Simona
Massone, Cesare
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title_full Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title_fullStr Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title_full_unstemmed Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title_short Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
title_sort histopathological markers for target therapies in primary cutaneous lymphomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670482/
https://www.ncbi.nlm.nih.gov/pubmed/37998391
http://dx.doi.org/10.3390/cells12222656
work_keys_str_mv AT sonegobenedetta histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas
AT ibaticiadalberto histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas
AT rivoligiulia histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas
AT angelucciemanuele histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas
AT solasimona histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas
AT massonecesare histopathologicalmarkersfortargettherapiesinprimarycutaneouslymphomas

Ejemplares similares